Axsome Therapeutics Purchases Baergic Bio from Avenue Therapeutics

Written by Emily J. Thompson, Senior Investment Analyst

ATXI%

AXSM+1.8%

Source: SeekingAlpha

Updated: Nov 06 2025

0mins

Source: SeekingAlpha

Avenue Therapeutics and Baergic Bio Deal: Avenue Therapeutics has agreed to sell its majority-owned subsidiary Baergic Bio to Axsome Therapeutics, which includes global rights to the epilepsy treatment AXS-17 (formerly BAER-101).
Financial Terms of the Agreement: The deal involves an upfront payment of $0.3M, potential development and sales milestone payments totaling up to $81.5M, and tiered royalties, with Avenue Therapeutics set to receive approximately 74% of future payments and royalties.
Axsome Therapeutics' Market Strategy: Axsome anticipates enhanced market access for its products SYMBRAVO and AUVELITY while continuing to advance its late-stage pipeline.
Axsome's Financial Performance: In its Q3 2025 earnings report, Axsome reported a GAAP EPS of -$0.94, which missed expectations, but its revenue of $171M exceeded forecasts by $8.01M.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Axsome Therapeutics Purchases Baergic Bio from Avenue Therapeutics

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Amazon's AI Growth Fuels Stock Rise, Nasdaq Predicted to Soar by 2026

Peter Thiel Sells Nvidia, Invests in Apple and Microsoft

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch